Harris Russell, Donahue Katrina, Rathore Saif S, Frame Paul, Woolf Steven H, Lohr Kathleen N
Sheps Center for Health Services Research, 725 Airport Road, CB # 7590, Chapel Hill, NC 27599-2949, USA.
Ann Intern Med. 2003 Feb 4;138(3):215-29. doi: 10.7326/0003-4819-138-3-200302040-00015.
Type 2 diabetes mellitus is associated with a heavy burden of suffering. Screening for diabetes is controversial.
To examine the evidence that screening and earlier treatment are effective in reducing morbidity and mortality associated with diabetes.
MEDLINE, the Cochrane Library, reviews, and experts, all of which addressed key questions about screening.
Studies that provided information about the existence and length of an asymptomatic phase of diabetes; studies that addressed the accuracy and reliability of screening tests; and randomized, controlled trials with health outcomes for various treatment strategies were selected.
Two reviewers abstracted relevant information using standardized abstraction forms and graded articles according to U.S. Preventive Services Task Force criteria.
No randomized, controlled trial of screening for diabetes has been performed. Type 2 diabetes mellitus includes an asymptomatic preclinical phase; the length of this phase is unknown. Screening tests can detect diabetes in its preclinical phase. Over the 10 to 15 years after clinical diagnosis, tight glycemic control probably reduces the risk for blindness and end-stage renal disease, and aggressive control of hypertension, lipid therapy, and aspirin use reduce cardiovascular events. The magnitude of the benefit is larger for cardiovascular risk reduction than for tight glycemic control. The additional benefit of starting these treatments in the preclinical phase, after detection by screening, is uncertain but is probably also greater for cardiovascular risk reduction.
The interventions that are most clearly beneficial during the preclinical phase are those that affect the risk for cardiovascular disease. The magnitude of additional benefit of initiating tight glycemic control during the preclinical phase is uncertain but probably small.
2型糖尿病与沉重的痛苦负担相关。糖尿病筛查存在争议。
检验筛查及早期治疗在降低糖尿病相关发病率和死亡率方面有效的证据。
MEDLINE、考克兰图书馆、综述及专家意见,所有这些均涉及有关筛查的关键问题。
选取提供有关糖尿病无症状期存在情况及持续时间信息的研究;涉及筛查试验准确性和可靠性的研究;以及针对各种治疗策略的健康结局的随机对照试验。
两名审阅者使用标准化提取表格提取相关信息,并根据美国预防服务工作组标准对文章进行分级。
尚未进行关于糖尿病筛查的随机对照试验。2型糖尿病包括无症状临床前期;此阶段的持续时间未知。筛查试验可在临床前期检测出糖尿病。在临床诊断后的10至15年里,严格的血糖控制可能降低失明和终末期肾病的风险,积极控制高血压、进行血脂治疗及使用阿司匹林可减少心血管事件。降低心血管风险的获益程度大于严格血糖控制。在筛查检测出的临床前期开始这些治疗的额外获益尚不确定,但可能在降低心血管风险方面也更大。
在临床前期最明显有益的干预措施是那些影响心血管疾病风险的措施。在临床前期开始严格血糖控制的额外获益程度尚不确定,但可能较小。